Literature DB >> 9764123

Hillside study of risk and early detection in schizophrenia.

B Cornblatt1, M Obuchowski, D Schnur, J D O'Brien.   

Abstract

BACKGROUND: The Hillside Study of Risk and Early Detection in Schizophrenia is a prospective study of young probands (ages 14-28) and their at-risk siblings (ages 14-24). A major goal is the identification of early predictors of illness that will facilitate intervention. The project design and pilot study are discussed.
METHOD: Fifteen adolescents were compared to 14 typical age-of-onset adults, all undergoing their first hospitalisation for schizophrenia.
RESULTS: There were no differences between adolescents and adults on any of the measures administered (i.e. attention, eye tracking, neurocognitive or clinical). In addition, for the sample overall, no association was found between neurocognitive functions and clinical state, either at admission or after treatment.
CONCLUSIONS: Individuals with adolescent onset of schizophrenia are considered to be representative of schizophrenia in general. Furthermore, neurocognitive deficits and clinical symptoms are concluded to be two independent classes of risk indicators.

Entities:  

Mesh:

Year:  1998        PMID: 9764123

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  8 in total

Review 1.  Converging models of schizophrenia--Network alterations of prefrontal cortex underlying cognitive impairments.

Authors:  Takeshi Sakurai; Nao J Gamo; Takatoshi Hikida; Sun-Hong Kim; Toshiya Murai; Toshifumi Tomoda; Akira Sawa
Journal:  Prog Neurobiol       Date:  2015-09-25       Impact factor: 11.685

2.  Neuropsychological correlates of diffusion tensor imaging in schizophrenia.

Authors:  Paul G Nestor; Marek Kubicki; Ronald J Gurrera; Margaret Niznikiewicz; Melissa Frumin; Robert W McCarley; Martha E Shenton
Journal:  Neuropsychology       Date:  2004-10       Impact factor: 3.295

3.  Neuropsychological functioning in adolescents and young adults at genetic risk for schizophrenia and affective psychoses: results from the Harvard and Hillside Adolescent High Risk Studies.

Authors:  Larry J Seidman; Anthony J Giuliano; Christopher W Smith; William S Stone; Stephen J Glatt; Eric Meyer; Stephen V Faraone; Ming T Tsuang; Barbara Cornblatt
Journal:  Schizophr Bull       Date:  2006-05-17       Impact factor: 9.306

4.  Cognitive and psychiatric predictors to psychosis in velocardiofacial syndrome: a 3-year follow-up study.

Authors:  Kevin M Antshel; Robert Shprintzen; Wanda Fremont; Anne Marie Higgins; Stephen V Faraone; Wendy R Kates
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-04       Impact factor: 8.829

5.  Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium.

Authors:  Tracy Alderman; Jean Addington; Carrie Bearden; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Kristin S Cadenhead
Journal:  Early Interv Psychiatry       Date:  2014-02-27       Impact factor: 2.732

6.  Predictors of remission, schizophrenia, and bipolar disorder in adolescents with brief psychotic disorder or psychotic disorder not otherwise specified considered at very high risk for schizophrenia.

Authors:  Christoph U Correll; Christopher W Smith; Andrea M Auther; Danielle McLaughlin; Manoj Shah; Carmel Foley; Ruth Olsen; Todd Lencz; John M Kane; Barbara A Cornblatt
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-10       Impact factor: 2.576

7.  The longitudinal course of attention deficit/hyperactivity disorder in velo-cardio-facial syndrome.

Authors:  Kevin M Antshel; Kaitlin Hendricks; Robert Shprintzen; Wanda Fremont; Anne Marie Higgins; Stephen V Faraone; Wendy R Kates
Journal:  J Pediatr       Date:  2013-01-18       Impact factor: 4.406

Review 8.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.